News
Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...
A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...
“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...
Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...
Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...
While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...
Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...
13d
Investor's Business Daily on MSNNovo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli LillyNovo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results